Stock Research: Takeda Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Takeda Pharmaceutical

TSE:4502 JP3463000004
33
  • Value
    8
  • Growth
    74
  • Safety
    Safety
    80
  • Combined
    55
  • Sentiment
    16
  • 360° View
    360° View
    33
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Takeda Pharmaceutical Co Ltd is a pharmaceutical company focused on research, development, and sale of pharmaceuticals. It focuses on gastrointestinal diseases, rare diseases, oncology, and neuroscience. The company operates in Japan, the United States, Europe, and China. In the last fiscal year, the company had a market cap of $46758 million, profits of $20016 million, and revenue of $30554 million, with 47455 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 33 (better than 33% compared with alternatives), overall professional sentiment and financial characteristics for the stock Takeda Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Takeda Pharmaceutical. The consolidated Value Rank has an attractive rank of 80, which means that the share price of Takeda Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 80% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 74, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 16. Professional investors are more confident in 84% other stocks. Worryingly, the company has risky financing, with a Safety rank of 8. This means 92% of comparable companies have a safer financing structure than Takeda Pharmaceutical. ...read more

more
Index
TOPIX 100
Nikkei 225
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
80 80 74 95
Growth
74 32 3 11
Safety
Safety
8 7 6 8
Sentiment
16 30 8 8
360° View
360° View
33 24 6 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
41 33 33 37
Opinions Change
46 83 24 50
Pro Holdings
n/a 24 14 32
Market Pulse
9 28 20 19
Sentiment
16 30 8 8
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
80 80 74 95
Growth
74 32 3 11
Safety Safety
8 7 6 8
Combined
55 18 6 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
39 26 30 71
Price vs. Earnings (P/E)
64 72 64 76
Price vs. Book (P/B)
76 83 73 87
Dividend Yield
96 93 98 96
Value
80 80 74 95
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
14 8 15 11
Profit Growth
83 23 6 14
Capital Growth
75 68 21 37
Stock Returns
78 60 49 65
Growth
74 32 3 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
17 14 7 4
Refinancing
20 19 11 25
Liquidity
26 16 22 18
Safety Safety
8 7 6 8

Similar Stocks

Discover high‑ranked alternatives to Takeda Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Megmilk Snow Brand

TSE:2270
Country: Japan
Industry: Packaged Foods & Meats
Size: Medium
Full Stock Analysis

Stanley Electric

TSE:6923
Country: Japan
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

Sankyu

TSE:9065
Country: Japan
Industry: Trucking
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.